Name Use Sample Clauses

Name Use. This Agreement does not convey any right to use any of the other Party's names or logos other than where required by law, rule or regulation. Neither Party may use publicly for publicity, promotion, or otherwise, any logo, name, trade name, service ▇▇▇▇ or trademark of the other Party or its Affiliates, or any simulation, abbreviation or adaptation of the same, or the name of any of the other Party's employee or agent without such other Party's prior, written, express consent other than where required by law, rule or regulation. MAYO's marks include, but are not limited to, the terms “MAYO®” and “MAYO CLINIC®.” Any violation of this Section 10.01 constitutes a material breach of this Agreement.

Name Use. Each Seller acknowledges and agrees, on its own behalf and on behalf of its respective Affiliates, that from and after the Closing, it renounces any and all rights to the use of the name “EdgeRock Technologies, LLC,” “EdgeRock Technology Partners” or similar names or any derivations thereof, and any trademarks and trade names containing or comprising the foregoing, and each Seller shall not, and shall not permit any of its Affiliates to, use such names or similar names and such trademarks and trade names.

Name Use. The Seller acknowledges that after the Closing the right of the Seller to use the name "The Pro Source Group, Inc." or any derivation thereof will be non-exclusive, and the Seller agrees (a) that from and after the Closing the Seller will use the name "The Pro Source Group, Inc." or any derivation thereof only in respect to the corporate functions of the Seller and/or in connection with the performance of contractual commitments of the Seller to Perd▇▇ ▇▇▇ms, Incorporated and (b) that the Seller will not later than September 30, 2001 change its corporate name to a name other than "The Pro Source Group, Inc." or any derivation thereof.

Name Use. Schering grants Pharmion a non-exclusive, royalty-free limited right and sub-license, under Schering's rights pursuant to the Aventis Supply Agreement, to use the "Aventis" name solely for the purpose of identifying Aventis as the Manufacturer on all Packaging materials, labels, inserts and any other printed matter included in the Product to the extent required by law, regulations and codes of practice in the Territory, on a country-by-country basis.

Name Use. The Shareholder and Brem▇▇ ▇▇▇ee that, except for the name "Recyc Trucking, Inc." neither will use, directly or indirectly through any subsidiary or affiliate, and each hereby waives, releases, relinquishes and assigns to Synagro the right to use, the names "Recyc, Inc." and "Recyc" and any other names containing the word "Recyc".

Name Use. Within three months following the Closing, the Seller and GTCR Holdings shall cease, and shall cause each of its controlled Affiliates to cease, using the “ConvergEx,” “Westminster” or any other names and marks owned by the Company or any of its Subsidiaries, and in furtherance of the foregoing shall cause, and shall cause each of its controlled Affiliates, including, but not limited to, ConvergEx Holdings LLC, to amend its respective organizational documents in order to change its name to delete the word “Convergex” or “Westminster,” as applicable. Each of the Seller and GTCR Holdings agrees that all rights in and interests to such name and marks, and all derivatives thereof, are the exclusive property of the Company.

Name Use. This Amended Agreement does not convey any right to use any of the other Party’s names or logos other than where required by law, rule or regulation. Neither Party may use publicly for publicity, promotion, or otherwise, any logo, name, trade name, service m▇▇▇ or trademark of the other Party or its Affiliates, or any simulation, abbreviation or adaptation of the same, or the name of any of the other Party’s employee or agent without such other Party’s prior, written, express consent other than where required by law, rule or regulation. MAYO’s marks include, but are not limited to, the terms “MAYO®” and “MAYO CLINIC®.” Any violation of this Section 10.01 constitutes a material breach of this Amended Agreement. Upon execution of this Amended Agreement, representatives of the Parties shall agree upon a mutually acceptable form of disclosure that can be utilized by either of them without obtaining the prior consent of the other Party.

Name Use. The Company shall take such actions as are necessary such that, immediately following the Merger Closing, all holders of Shares shall cease, and shall cause each of its controlled Affiliates to cease, using the “▇▇▇▇▇▇▇▇▇▇ Investment Company, Inc.,” “▇▇▇▇▇▇▇▇▇▇ Securities, Inc.” or any other names and marks owned by the Company, other than in connection with their employment by Purchaser or its Affiliates following the Merger Closing.

Name Use. (a) After the Closing Date, APBI and its affiliates shall retain all rights to, and Buyer agrees that it and no member of the UK Transfer Group shall have any right to, the name "Pharmaco" and any derivative thereof or similar name thereto. The Buyer agrees that APBI and its affiliates may use the name "Pharmaco LSR" in the conduct of its business, for the period of six months following the Closing Date after which it will cease using the name LSR either alone or in conjunction with the Pharmaco name. APBI and its affiliates shall also retain all rights under any trademark or service ▇▇▇▇ registrations or applications with respect to the name or ▇▇▇▇ "Pharmaco LSR"; provided, that such registrations shall only be used to protect APBI's or its affiliate's use of the name Pharmaco and derivatives thereof. Promptly following the Closing, Buyer shall cause the UK Subsidiary to change its name to a name that does not include "Pharmaco" or any name that is otherwise confusingly similar. (b) Each of APBI and the US Subsidiary hereby agree that the Buyer, directly or through its affiliates or subsidiaries, shall be entitled to whatever rights either of them or their affiliates may have in or to the names "LSR," "Life Science Research" and "Biodynamics" and any derivatives thereof (excluding "Pharmaco LSR").